Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


12.11.2018

1 AJR Am J Roentgenol
1 Am J Clin Pathol
5 Anticancer Res
2 BMC Cancer
1 BMC Urol
2 Cancer
2 Cancer Res
1 Eur Radiol
4 Eur Urol
1 Int J Cancer
1 Invest Radiol
2 J Natl Med Assoc
6 J Urol
1 Oncogene
1 PLoS One
1 Prog Urol
1 Prostate
1 Urol Int


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. PARVINIAN A, Martin-Macintosh EL, Goenka AH, Durski JM, et al
    11C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas.
    AJR Am J Roentgenol. 2017 Nov 15:1-5. doi: 10.2214/AJR.17.18312.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. VOLLMER RT
    Serum Prostate-Specific Antigen (PSA) Concentration, PSA Mass, and Obesity: A Mathematical Analysis.
    Am J Clin Pathol. 2018;149:262-266.
    PubMed     Text format     Abstract available


    Anticancer Res

  3. SAK K, Lust H, Kase M, Saar M, et al
    Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
    Anticancer Res. 2018;38:6209-6215.
    PubMed     Text format     Abstract available

  4. KOH M, Kim YS, Ahn H, Kim CS, et al
    Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer.
    Anticancer Res. 2018;38:6579-6584.
    PubMed     Text format     Abstract available

  5. CHO SY, Kang S, Kim DS, Na HJ, et al
    HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer.
    Anticancer Res. 2018;38:6551-6560.
    PubMed     Text format     Abstract available

  6. HEATH EI, Heilbrun LK, Smith D, Schopperle WM, et al
    Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.
    Anticancer Res. 2018;38:6361-6366.
    PubMed     Text format     Abstract available

  7. WANG C, Sargsyan D, Zhang C, Wu R, et al
    Transcriptomic Analysis of Histone Methyltransferase Setd7 Knockdown and Phenethyl Isothiocyanate in Human Prostate Cancer Cells.
    Anticancer Res. 2018;38:6069-6083.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. ZEIGLER-JOHNSON C, Hudson A, Glanz K, Spangler E, et al
    Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort.
    BMC Cancer. 2018;18:1061.
    PubMed     Text format     Abstract available

  9. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Text format     Abstract available


    BMC Urol

  10. MANNAERTS CK, Wildeboer RR, Postema AW, Hagemann J, et al
    Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens.
    BMC Urol. 2018;18:98.
    PubMed     Text format     Abstract available


    Cancer

  11. PRINTZ C
    New drug option for men with aggressive prostate cancer.
    Cancer. 2018;124:3797.
    PubMed     Text format    

  12. RESNICK MJ, Graves AJ, Gambrel RJ, Thapa S, et al
    The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.
    Cancer. 2018 Nov 9. doi: 10.1002/cncr.31700.
    PubMed     Text format     Abstract available


    Cancer Res

  13. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Text format     Abstract available

  14. ROSSNAGL S, Ghura H, Groth C, Altrock E, et al
    A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
    Cancer Res. 2018;78:129-142.
    PubMed     Text format     Abstract available


    Eur Radiol

  15. LARBI A, Omoumi P, Pasoglou V, Michoux N, et al
    Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.
    Eur Radiol. 2018 Nov 9. pii: 10.1007/s00330-018-5796.
    PubMed     Text format     Abstract available


    Eur Urol

  16. PLOUSSARD G, Gandaglia G, Borgmann H, de Visschere P, et al
    Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30836.
    PubMed     Text format     Abstract available

  17. CANTER DJ, Reid J, Latsis M, Variano M, et al
    Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30816.
    PubMed     Text format     Abstract available

  18. CHIU PK, Ng CF, Semjonow A, Zhu Y, et al
    A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
    Eur Urol. 2018 Nov 2. pii: S0302-2838(18)30842.
    PubMed     Text format     Abstract available

  19. GANDAGLIA G, Soligo M, Battaglia A, Muilwijk T, et al
    Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30837.
    PubMed     Text format     Abstract available


    Int J Cancer

  20. YUAN C, Shui IM, Wilson KM, Stampfer MJ, et al
    Circulating 25-hydroxyvitamin D, vitamin D binding protein, and risk of advanced and lethal prostate cancer.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31966.
    PubMed     Text format     Abstract available


    Invest Radiol

  21. MAI J, Abubrig M, Lehmann T, Hilbert T, et al
    T2 Mapping in Prostate Cancer.
    Invest Radiol. 2018 Nov 2. doi: 10.1097/RLI.0000000000000520.
    PubMed     Text format     Abstract available


    J Natl Med Assoc

  22. REDDY A, Roberts R, Shenoy D, Packianathan S, et al
    Prostate Cancer Screening Guidelines for African American Veterans: A New Perspective.
    J Natl Med Assoc. 2018 Nov 5. pii: S0027-9684(18)30284.
    PubMed     Text format     Abstract available

  23. COBRAN EK, Young HN, Chen RC, Chen X, et al
    Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
    J Natl Med Assoc. 2018 Oct 30. pii: S0027-9684(18)30168.
    PubMed     Text format     Abstract available


    J Urol

  24. TANEJA SS
    Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Urol. 2018;200:498-499.
    PubMed     Text format    

  25. TANEJA SS
    Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological Features.
    J Urol. 2018;200:497-499.
    PubMed     Text format    

  26. RESNICK MJ
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;200:488-489.
    PubMed     Text format    

  27. KRIMPHOVE MJ, Fletcher SA, Cole AP, Berg S, et al
    Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
    J Urol. 2018 Nov 8. pii: S0022-5347(18)44053-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  28. TANEJA SS
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System.
    J Urol. 2018;200:499.
    PubMed     Text format    

  29. ATALA A
    Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.
    J Urol. 2018;200:501-502.
    PubMed     Text format    


    Oncogene

  30. PAI VC, Hsu CC, Chan TS, Liao WY, et al
    Correction: ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling.
    Oncogene. 2018 Nov 2. pii: 10.1038/s41388-018-0561.
    PubMed     Text format     Abstract available


    PLoS One

  31. ZHANG X, Lin Y, Xie X, Shen M, et al
    Is acne in adolescence associated with prostate cancer risk? Evidence from a meta-analysis.
    PLoS One. 2018;13:e0206249.
    PubMed     Text format     Abstract available


    Prog Urol

  32. ROZET F, Hennequin C, Beauval JB, Beuzeboc P, et al
    [French ccAFU guidelines - Update 2018-2020: Prostate cancer].
    Prog Urol. 2018 Nov 1. pii: S1166-7087(18)30514.
    PubMed     Text format     Abstract available


    Prostate

  33. GIULIANELLI R, Nardoni S, Bruzzese D, Falavolti C, et al
    Urotensin II receptor expression in prostate cancer patients: A new possible marker.
    Prostate. 2018 Nov 8. doi: 10.1002/pros.23734.
    PubMed     Text format     Abstract available


    Urol Int

  34. FERRO M, Musi G, Serino A, Cozzi G, et al
    Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
    Urol Int. 2018 Nov 8:1-8. doi: 10.1159/000494259.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: